Tesamorelin vs Lactoferricin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Lactoferricin
Lactoferricin is an antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. It has potent antibacterial, antiviral, and antifungal properties.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Lactoferricin |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Binds to and disrupts microbial membranes through electrostatic interactions. Also binds to lipopolysaccharide (LPS) to neutralize endotoxins and has immunomodulatory effects. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Research applications vary widely. Oral lactoferrin supplements (containing lactoferricin precursor) typically dosed at 100-400mg daily. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Available through lactoferrin supplementation orally. Purified lactoferricin primarily used in research settings. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Lactoferrin supplementation is generally well-tolerated. May cause GI upset in some individuals. Derived from milk so caution with dairy allergies. |
| Best For |